Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Between 2023 and 2030, an estimated $200 B in annual revenue is at risk due to loss of exclusivity (LoE). 2026 Watchlist: Key blockbusters like Eliquis(apixaban), Januvia(sitagliptin), and Xeljanz(tofacitinib) will face intense pressure, forcing a rapid shift toward M&A and pipeline acquisition to fill the revenue gap
Los sistemas de farmacovigilancia, como el de la AEMPS y la EMA, dependen en gran medida de los reportes espontneos para detectar seales de seguridad que no se evidencian en los ensayos clnicos iniciales
Li Y, He Y, Chen G et al (2021) Selenomethionine protects oxidative-stress-damaged bone-marrow-derived mesenchymal stem cells via an antioxidant effect and the PTEN/PI3K/AKT pathway
Abu-Al hayl, A
US$ 23.03
US$ 25.51
US$ 24.13
